Attend Cell

A new era is emerging in cell and gene therapy where innovation in bioprocessing, manufacturing, and therapeutic development is accelerating at pace.

Do you have the insights, technologies, and partnerships to lead this transformation? Cell brings together the full cell culture and advanced therapy community—from early discovery to commercial delivery. Across three focused programmes, this is where ideas scale, data drives action, and next-gen therapies come to life.

We’re building a global network of pharma, biotech, academia, and regulatory leaders, shaping the future of advanced therapy production and delivery. From optimising cell systems and engineering scalable platforms, to integrating AI and next-gen manufacturing tools— Cell is your access point to the breakthroughs redefining the industry.

This programme spans three programmes exploring the entire value chain involved in bringing the next generation cell & gene therapies to market.

1000

leading pharma, biotech, regulatory & academic delegates

700

pre-arranged 1-2-1 meetings, facilitating business growth

hours of presentations, discussions & interactive content

hours of networking breaks, including fireside chats & refreshments

Be part of the breakthrough
Our events are where innovations land.
Be at the showcase and meet the people behind the technologies.

Survey the competitive landscape
Gain a holistic view of the cell & gene therapy pipeline.
Learn what others like you are doing and set your benchmarks.

Join the conversation
Meet like-minded peers, expand your network and engage in interdisciplinary discussion on the latest thinking and practice.

Bridge your knowledge gaps
Let subject specialists take you deeper. We span the entire cell & gene therapy value chain, including cell culture, bioprocessing, and advanced therapies.

Accelerate your work
Discover and adopt the data and machine-learning tools that will be critical in removing bottlenecks, automating processes and unlocking growth.

Build partnerships that last
Target the people your strategy requires. Sit down together, explore synergies and cement the relationships you’ll need for the longterm.

Networking & knowledge-sharing is at the heart of what we do, with 700 pre-arranged 1-2-1 meetings and over 12 hours of networking solutions don't miss the opportunity to connect with 1,000 leaders from across pharma, biotech, regulatory and academia.

Engaging Thought Leadership
Experience over 200 interactive discussions, thought leadership debates, and collaborative roundtables, with insights from industry leaders to benchmark your research & development pipeline.

Pre-Event Day
Begin your Cell experience with focused sessions addressing core challenges - explore novel approaches to cell line development, gain valuable perspectives on gene therapy pipelines, and compare autologous versus allogeneic strategies.

Networking Emphasis
Unparalleled networking opportunities, including personalised 1-2-1 meetings, a start-up zone, vibrant drinks reception, gala dinner, and informal gatherings to foster meaningful connections.

Innovation & Collaboration Programme Track
Inspiring presentations unveiling the latest breakthroughs from emerging biotech, pharma, and start-up companies.

Purposeful Roundtable Discussions
Kick off Day 2 with engaging, expert-led roundtables over coffee and pastries—designed to spark discussion, share insights, and connect with peers around the most pressing challenges in cell and gene therapy.

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow; and Lundbeck Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Roundtable: Regulatory Insights On Bringing A Peptide To Human Trials

Moderator: Paul Reid, Co-Founder & Chief Scientific Officer, Celtic Bio

Oligonucleotides
Workshop: Development Of Targeted Delivery Systems

Two Presentations, followed by a Panel Discussion on 'The Next Chapter Of Oligonucleotide Delivery'
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies?

Presented by: Daniel Larocque, Innovation Lead, Innovation and Emerging Science, Sanofi

Anna Perdrix

CEO,

Sixfold Bioscience

Fernando Albericio

Professor,

University of KwaZulu-Natal

Kelly Loyet

Distinguished Scientist,

Genentech

Kevin Fitzgerald

Chief Scientific Officer,

Epsilogen

Livija Deban

Chief Scientific Officer,

Prokarium

Maria Koufali

Director,

UK Vaccine Innovation Pathway

Marta Amaral

Head High Throughput Protein Engineering in Large Molecules Research,

Sanofi

Nazneen Dewji

Chief Executive Officer,

Cenna Biosciences Inc.

Philip Beer

CSO,

Step Pharma

Rick Hibbert

Vice President & Head of CMC Science & Technologies,

Genmab

Sudhir Agrawal

Founder,

Arnay Sciences

Tristan Vaughan

Vice President Protein Engineering,

Immunocore

Aaron John Balana

Scientist III,

Genentech

Aikaterini Gatsiou

Assistant Professor,

Lancaster University

Alain Wagner

Research Director,

Strasbourg University

Alastair Lawson

Vice President,

UCB

alessandra tolomelli

professor,

university of Bologna

Alessandro Gori

Group Leader,

National Research Council of Italy

Alexandria Cogdill

Head of Strategic Initiatives, Global Business Development,

Daiichi Sankyo, Inc

Álvaro Enríquez García

Medicinal Chemist,

Eli Lilly

Amita Vaidya

Principal Scientist,

Sanofi

Ammar Ahmed

Senior Scientist,

Imperial College London

Amy Li

Director, Drug Discovery,

T-Therapeutics Ltd

Anand Kumar

Senior Scientist,

Sanofi

Andreas Reichel

Vice President, Head of Research Pharmacokinetics,

Bayer

Andreas Midbøe Hoff

Head of In Silico & AI Department,

Nykode

Andrew Slee

Chief Operating Officer,

AgenusBio

Andrew Jamieson

Professor Of Chemical Biology ,

University of Glasgow

Andrew Buchanan

Principal Scientist: Biologics Engineering,

AstraZeneca

Andrew Creese

Associate Director,

Immunocore

Andri Vasou

Head of Platform Development,

Bioarchitech

Aneesh Karatt Vellatt

Chief Scientific Officer,

Maxion Therapeutics

Anna Hine

Professor of Protein Engineering,

Aston University

Anna Maria Papini

Full Professor and Group Leader of PeptLab,

University of Florence

Annelise Vuidepot, PhD

SVP CTO - Head of Pipeline & Platform Research and UK site Head,

Immunocore

Antonio Postigo

Chief Scientific Officer,

Stratosvir

Aswin Doekhie

Chief Technology Officer,

Ensilicated Technologies Ltd

Baldur Sveinbjørnsson

Chief Scientific Officer,

Lytix Biopharma

Bassam Hallis

Deputy Director of Research and Evaluation,

UK Health Security Agency

Benjamin Lindner

Data Scientist,

Boehringer Ingelheim RCV GmbH & Co KG

Berit Olsen Krogh

Senior Research Fellow,

Lundbeck

Bernard Maillere

Head of Laboratory,

CEA

Bjorn Onfelt

Professor of Applied Physics,

Royal Institute of Technology

Brian Schanen

Global Head of Biomarkers,

Sanofi

Caleb McClain

Chief Executive Officer,

ANUNA (AI+BIO)

Callum Scott

Head of Development,

Scancell Ltd

Carla Vinals

Vice President, Global Regulatory Product Strategy,

Moderna Therapeutics

Carol Sze Ki Leung

Principal Investigator ,

Ludwig Institute, Oxford University

Charlotte Vernhes

Scientific and Medical Affairs Director,

Vaccines Europe

Christian Garde

Scientific Director, Bioinformatics,

Evaxion A/S

Christopher Scott

Professor,

Queen's University Belfast

Dan Hardy

CEO,

Microsol

Daniel Larocque

Innovation Lead, Innovation and Emerging Science,

Sanofi Vaccines

Daniel Fonseca

Senior Research Scientist I ‑ Experimental Immunology,

Immunocore

Daniel Sejer Pedersen

Chemical Development Specialist,

Novo Nordisk A/S

David Craik

Professor,

The University of Queensland

David Brockwell

Professor,

University of Leeds

David Pejoski

Co-founder, Co-Chief Executive Officer, Chief Operating Officer, & Board Member,

Adoram Therapeutics

David Wraith

Professor,

UNIVERSITY OF BIRMINGHAM

Denise Steckel

Head of Clinical Collaborations Development,

Genentech

Deniz Eris

Principal Scientist,

Novartis

Dorothy Bray

Senior Executive,

Celtic Biotech

Ed Tate

Professor,

Imperial College London

Eef Dirksen

Director Analytical Development & Quality Control,

Byondis B.V.

Elisa Marelli

Research Scientist,

Scancell

Elizabeth Boulter

Senior Scientist,

AstraZeneca

Erik Vernet

VP,

Novo Nordisk

Ernst Weber

Head of Molecular Design & Engineering & Bayer Science Fellow,

Bayer AG

Etienne Matous

Head of Lead Optimisation,

Iginnovate

Fazel Shabanpoor

Lab Head Peptide And Oligonucleotide Therapeutics,

The Florey Institute of Neuroscience and Mental Health

Felix Schumacher

Program Leader Targeted Therapeutics,

Roche

Francisca Wollerton

Senior Director,

AstraZeneca

Gabriel Wong

Senior Medical Director,

AstraZeneca

Georgios Skretas

Director,

Biomedical Sciences Research Center "Alexander Fleming"

Giulio Russo

Senior Scientist,

Merus

Hans Melo

Chief Executive Officer,

Menten Biotechnology Labs

Hans Van Der Vliet

Chief Scientific Officer,

LAVA Therapeutics

Helen Bright

Chief Scientific Officer,

Centauri Therapeutics

Helene Kaplon

Translational Scientist,

Servier

Henry Maun

Staff Scientist,

Genentech

Hester Van Zeeburg

Project Manager Immune & Disease Monitoring,

Mendus AB

Ian Hamley

Professor of Physical Chemistry,

University of Reading

Ijeoma Uchegbu

Professor of Pharmaceutical Nanoscience,

University College London

Immanuel Lerner

Chief Executive Officer,

Pepticom

Isabelle Sermadiras

Associate Principal Scientist,

AstraZeneca

Itishri Sahu

Program Lead Therapeutics,

Ziphius Vaccines

Iulia Oita

CMC Manager,

Ziphius Vaccines

Janos Tibor Kodra

Principal Scientist,

Novo Nordisk

Jean Ge

Patent Attorney,

Wolf Greenfield

Jennifer Percival-Alwyn

Scientific Leader,

GSK

John Maher

Chief Scientific Officer,

Leucid Bio

Jonathan Kwok

Chief Executive Officer,

Infinitopes

Joost Uitdehaag

Head of Biology,

Crossfire Oncology B.V.

Jörg Wischhusen

Professor,

University Hospital Würzburg

Jutta Eichler

Professor Medicinal Chemistry,

University of Erlangen-Nurnberg

Karen Silence

Vice President,

Argenx BVBA

Kate Smith

Head of Protein,

GSK

Ken Chow

Health Tech Counsel,

Flanders Investment & Trade

Kerry Chester

Professor of Molecular Medicine, Research Department of Oncology - University College London, Director at The Antibody Society,

The Antibody Society

Kevin Maskell

Research Director,

Bioarchitech

Knud Jørgen Jensen

Professor,

Copenhagen University

Kuda Muchandibaya

Lecturer for Supply Chain Management & Logistics,

Rhine-Waal University of Applied Sciences

Laura Starkie

Director,

UCB

Laura Collins

Director Bioinformatics,

Immunocore

Leonardo De Maria

Principal Scientist,

AstraZeneca

Louis Diorazio

Senior Principal Scientist,

AstraZeneca

Lucia Ferrazzano

Junior Assistant Professor,

University of Bologna

Lukas Pekar

Lab Head,

Merck

Mads Hald Andersen

Professor,

National Centre For Cancer Immune Therapy (CCIT-dk)

Mani Mudaliar

Director, Quantitative Biomarkers,

Recursion

Marc Vendrell Escobar

Professor of Translational Chemistry,

University of Edinburgh

Maria Fawaz

Associate Principal Scientist,

MSD

Marie McAvoy

Chief Scientific Officer,

Nanosyrinx

Marina Fedorova

Scientific Investigator,

GSK

Mark Eccleston

CEO,

Valirx Plc

Markus Templin

Head - Cellular & Molecular Biology,

NMI

Martina Ochs

Project Leader,

CEPI

Mathieu Cinier

Scientific Director,

Affilogic

Matthew Burrell

Associate Director,

AstraZeneca

Mattias Malm

Senior Scientist,

Ferring Pharmaceuticals

Micaela Graglia

Analytical Chemist, Molecular Design,

Silence Therapeutics

Michael Delaney

Senior Principal Scientist,

Novo Nordisk

Mihaela Bozic

Scientist,

T-Therapeutics Ltd

Mikhail Kuravsky

Principal Scientist,

UCB

Nathan Alves

Research Director,

Indiana University School of Medicine

Nesrine Chakroun

Associate Director,

Merus NV

Nicola Ferrari

Director,

AstraZeneca

Norbert Furtmann

Head of AI Innovation NANOBODY® Platform,

Sanofi

Obinna Ubah

Principal Scientist,

Elasmogen Limited

Owen Vickery

Associate Principal Scientist,

AstraZeneca

Patricia Alves

Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,

Instituto de Biologia Experimental e Tecnológica

Paul Wassmann

Senior Principal Scientist,

Novartis AG

Pawel Stocki

Vice President,

Ossianix

Peter Sondermann

Chief Executive Officer,

Tacalyx GmbH Privacy Policy Imprint

Prasun Chakraborty

Founder & CEO,

Genevation LTD

RaJ Mehta

CEO,

Adendra Therapeutics

Raymond Tesi

President & Chief Executive Officer,

InMune Bio

Reeta Daswani

Senior Scientist II,

Sixfold Biosciences

Rita Martello

Scientific Director, NBE DMPK Lead,

Merck KGaA

Robert Andrews

Partner,

Mewburn Ellis LLP

Rodrigo Abreu

Principal Scientist,

LifeArc

Russell LaMontagne

CEO,

BITT

Sagar Kathuria

Sr. Scientist, Protein Engineering I,

Sanofi

Sandor Batkai

Freelance Consultant,

Cardior Pharmaceuticals

Sandra Tremmel

Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,

Roche

Sandrien Janssens

CMC Director,

Mosanna Therapeutics

Santiago Parpal

Principal Scientist,

Sprint Bioscience

Sarah Stuart

High Throughput Characterisation Team Leader,

GSK

Sarah Hindson

Senior Scientist,

GSK

Saurabh Sen

Associate Director, Cell Line Development, Mammalian Platform Biologics,

Sanofi

Sebastian Sten

Associate Principal Scientist,

AstraZeneca

Sevim Ozgur Bruderle

Lab Head,

Sanofi

Shao-An Xue

Senior Scientist,

University College London

Silvia Crescioli

Business Intelligence Creator,

The Antibody Society

Simon Hufton

Section Head Molecular Immunology, Division of Biotherapeutics,

MHRA

Simone Friedrich

Director Antibody Discovery & Development,

iOmx Therapeutics

Sonia Macia

Chief Medical Officer,

Aromics Therapeutics

Sonja Merkas

Founder, Creator & Doer,

Livinovea

Sophia Karagiannis

Professor of Translational Cancer Immunology and Immunotherapy,

King's College London

Sritama Bose

Associate Director of Chemistry,

Nucleic Acid Therapy Accelerator, Medical Research Council (UKRI)

Stefan Zielonka

Senior Director, Global Head of Antibody Discovery & Protein Engineering,

Merck KGaA

Stephen Miller

Principal Scientist,

Genentech

Steve Hood

Senior Director,

GSK

Steven Schmitt

Co-Founder & Chief Executive Officer,

Myria Biosciences

Stine Friis Thorsen

Director Clinical Development,

Evaxion Biotech

Sue Charlton

Head of Clinical Evaluation,

UK Health Security Agency

Talip Ucar

Founding Member MTS,

Boltz

Tatyana Ponomaryov

Principal Scientist,

Plasticell

Thomas Kraft

Principal Scientist,

Roche

Thomas Powell

Senior Scientist,

Immunocore

Timothy Hickling

Immunogenicity Expert Scientist,

Roche

Tomasz Witkos

Associate Director,

AstraZeneca

Toria Legh-Land

Modelling Lead,

Microsol

Trevor Smith

Vice President,

Inovio

Ulrike Rieder

Scientific Lead,

Novartis

Vaios Karanikas

Biomarker Portfolio Leader,

Roche

Vik Reebye

Head of Academic Partnerships ,

MiNA Therapeutics Ltd

Vincent Dewar

Head of Immunoassay,

GSK

Vincenzo de Filippis

Associate Professor Biochemistry,

University of Padova

Walter Cabri

Professor,

Fresenius Kabi

Wen-Hsuan Chang

AVP Discovery and Early Development,

AcuraStem

Will Nesbit

Senior Director - Process Chemistry & CMC,

Bicycle Therapeutics

Wolfgang Koch

Senior Scientist,

F-star Therapeutics Inc

Yann Abraham

Associate Director AI for Single Cell,

Johnson & Johnson Innovative Medicine

Yiping Wu

Senior Scientist,

AstraZeneca

Zahra Rattray

Senior Lecturer,

University of Strathclyde

Zinaida Dedeic

Senior Scientist,

University of Oxford